A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement factor H.

 
Web www.patentalert.com

< Therapeutic peptides and vaccines

< Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

> Alpha-ketoamides and derivatives thereof

> Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor
~ 00600